These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26663401)

  • 21. Brivaracetam efficacy and safety in focal epilepsy.
    Makke Y; Abou-Khalil B
    Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
    [No Abstract]   [Full Text] [Related]  

  • 22. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
    Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA
    Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.
    Estrada S; Lubberink M; Thibblin A; Sprycha M; Buchanan T; Mestdagh N; Kenda B; Mercier J; Provins L; Gillard M; Tytgat D; Antoni G
    Nucl Med Biol; 2016 Jun; 43(6):325-32. PubMed ID: 27260773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.
    Talos DM; Chang M; Kosaras B; Fitzgerald E; Murphy A; Folkerth RD; Jensen FE
    Pediatr Res; 2013 Jan; 73(1):24-30. PubMed ID: 23138400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.
    Zona C; Pieri M; Carunchio I; Curcio L; Klitgaard H; Margineanu DG
    Epilepsy Res; 2010 Jan; 88(1):46-54. PubMed ID: 19914041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brivaracetam in the treatment of epilepsy: a review of clinical trial data.
    Feyissa AM
    Neuropsychiatr Dis Treat; 2019; 15():2587-2600. PubMed ID: 31571877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
    Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
    Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals.
    Beaty S; Rosenthal NA; Gayle J; Dongre P; Ricchetti-Masterson K
    Front Neurol; 2021; 12():760855. PubMed ID: 34912285
    [No Abstract]   [Full Text] [Related]  

  • 34. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam.
    Meador KJ; Gevins A; Leese PT; Otoul C; Loring DW
    Epilepsia; 2011 Feb; 52(2):264-72. PubMed ID: 20887370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus.
    Willems LM; Bauer S; Rosenow F; Strzelczyk A
    Expert Opin Pharmacother; 2019 Oct; 20(14):1755-1765. PubMed ID: 31264486
    [No Abstract]   [Full Text] [Related]  

  • 37. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
    Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats.
    Ge YX; Lin YY; Bi QQ; Chen YJ
    Curr Neurovasc Res; 2020; 17(4):354-360. PubMed ID: 32407277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brivaracetam: a novel antiepileptic drug for focal-onset seizures.
    Stephen LJ; Brodie MJ
    Ther Adv Neurol Disord; 2018; 11():1756285617742081. PubMed ID: 29399049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.